Takeda Establishes "Takeda Global Advisory Board"

Takeda Establishes "Takeda Global Advisory Board"

Posted on:24 Jun 09.Osaka, Japan, June 23, 2009 - Takeda Pharmaceutical Company Limited ("Takeda") today announced the establishment of the Takeda Global Advisory Board ("TGAB") as part of its vision to become a global pharmaceutical company with strong corporate governance.

By incorporating both members of Takeda's current executive management as well as four external Advisors with executive level experience at global pharmaceutical companies, the TGAB will discuss and provide the company with valuable guidance on a variety of managerial topics, including innovative medical technologies under the rapidly changing environment surrounding the pharmaceutical industry.

"Takeda is making meaningful changes in its governance through the establishment of Takeda Global Advisory Board and the inclusion of external Advisors," said Yasuchika Hasegawa, President, Takeda Pharmaceutical Company Limited. "By leveraging the expertise of our external industry leaders, Takeda looks forward to continuing creating and marketing novel pharmaceutical products that meet the needs of patients globally."

External Members of the Takeda Global Advisory Board (in alphabetical order):
- Ms. Karen Katen, former Vice Chairman of Pfizer Inc. and currently Senior Advisor for Essex Woodlands Health Ventures
- Dr. Frank Morich, former CEO of Bayer HealthCare and currently CEO of NOXXON Pharma
- Mr. Sidney Taurel, former Chairman and CEO of Eli Lilly & Co. and currently Chairman Emeritus of Eli Lilly & Co.
- Dr. Tadataka Yamada, former chairman of Research and Development and member of the Board of Directors at GlaxoSmithKline and currently President of the Global Health Program at the Bill & Melinda Gates Foundation

Profiles of External Members of Takeda Global Advisory Board


Karen Katen, MBA
Graduated from The University of Chicago
1974: Received MBA(The University of Chicago)
1974: Joined Pfizer Inc. as a Management Associate
1983: General Manager, Marketing, Pfizer
1995: President, Pfizer U.S. Pharmaceuticals
1999: Executive Vice President, Pfizer Pharmaceuticals Worldwide
2001: President, Pfizer Pharmaceuticals Worldwide
2005: Vice Chairman of Pfizer Inc. and President of Pfizer Human Health
2007: Joined Essex Woodlands Health Ventures as a Senior Advisor, Director on the boards of General Motors Corporation, the Harris Corporation, The Home Depot and Air Liquide.

Frank Morich, MD, PhD
Graduated in Medicine at the University of Marburg , specializing in immunology and oncology
1982: Joined Bayer AG's Pharmaceutical Division; Head of Global Research & Development and Global Product Development
1998: General Manager of Bayer AG's Consumer Care Division
2000: Member of the Board of Management, Bayer AG and BOD Bayer Corp
2002: Chairman of the Board of Management, Bayer HealthCare, and Member of the Senate, Fraunhofer Society for Applied Research
2004: CEO, AM-Pharma; Chairman, Scientific Advisory Board, Forbion; BOD Innate Pharma
2005: CEO and Member BOD, Innogenetics; BOD AM-Pharma
2008: CEO NOXXON Pharma

Sidney Taurel, MBA
Graduated from École des Hautes Études Commerciales
1971: Received MBA(Columbia University)
1971: Joined Eli Lilly International Corporation as a marketing associateand experienced various positions in Latin America and Europe
1983: Vice president of Lilly European Operations
1986: President, Eli Lilly International Corporation
1993: President, Pharmaceutical Division, Eli Lilly and Company
1996: President and COO, Eli Lilly and Company
1998: CEO, Eli Lilly and Company
1999: CEO and Chairman of the board of directors, Eli Lilly and Company
2008: Chairman of the board of directors, Eli Lilly and Company
2009: Chairman Emeritus, Eli Lilly and Company

Tadataka Yamada, MD
Graduated from Stanford University and received his medical degree from New York University.
Former chairman of the Department of Internal Medicine at the University of Michigan Medical School and Physician-in-Chief at the University of Michigan Medical Center
2001: Appointed CSO of GSK
2004: Member of BOD of GSK (until May 2006)
2006: Joined Bill and Melinda Gates Foundation, President of Global Health Program

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.